Navigation Links
Anesiva Defines Regulatory Pathway for Adlea with FDA
Date:10/10/2007

New Phase 3 Plan Could Expedite Clinical Development Pathway

SOUTH SAN FRANCISCO, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it will conduct two Phase 3 clinical trials for the approval of Adlea(TM) -- one of which has already been planned in total knee replacement surgeries -- and the second trial in bunionectomy surgeries -- for a broad product label of management of post-surgical pain associated with orthopedic surgeries. This decision is the result of continuing conversations with the Food and Drug Administration (FDA). Adlea is the company's long-acting, non-opiate analgesic drug candidate designed to provide pain relief for weeks to months after a single local application during a surgical procedure. Anesiva has already demonstrated statistically significant pain reduction in Phase 2 trials in both of these settings. Both trials are expected to begin in the first half of 2008.

"We are very pleased with this agreement with the FDA. Some of our strongest clinical efficacy data for Adlea came from a Phase 2 bunionectomy trial of 185 patients, where Adlea resulted in statistically significant reductions in both post-surgical pain as well as the use of rescue medication," said John P. McLaughlin, chief executive officer of Anesiva. "Bunionectomy is an excellent choice for a second Phase 3 study because it is a well studied and validated pain model. In addition, bunionectomy studies are efficient and can be conducted rapidly."

Two prior randomized, double-blind, placebo-controlled Phase 2 bunionectomy trials evaluating the use of Adlea to reduce post-surgical pain yielded favorable results. The first trial was a Phase 2 study of 40 patients that s
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis
3. Stanford Researchers Find Brain Pathway of Depression in Rats
4. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
5. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
6. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
7. Researchers Identify Intracellular Pathway of Alfacells Onconase

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...ON, Calif., Nov. 9 Thora...n device-based mechanical circulatory support ther... said today that it will be participating in the T... Tuesday, November 10. ,, The presentation by G...cer, will begin at 8 a.m., Pacific Standard Time (...
(Date:11/9/2009)... Mass., Nov. 9 Hologic, ...leading developer, manufacturer and supplier of pr...gical products dedicated to serving the healthcare...he fourth quarter and fiscal year ended September ... Board of Directors has promoted Robert Cascella t...
(Date:11/9/2009)..., PRINCETON, N.J., Nov. 9 /PRNewswire-FirstCall/...nagement will present at the Sixth Annual Lazard C...ce will be held at the St Regis Hotel in New York ... Pharmasset,s President and Chief Executive Office...esday, November 18, 2009 at 3:45 PM (ET). ,, To...
Breaking Medicine Technology:Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 2Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 3Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 4Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 5Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 6Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 7Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 8Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 9Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 10Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 11Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 12Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 13Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 14Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 15Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 16Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 17Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 18Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 19Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 20Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 21Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 22Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 23Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 24Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 25Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 26Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 27Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results 28Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3FDA Clears a Test for Ovarian Cancer 4972 1FDA Clears a Test for Ovarian Cancer 4972 2Professor Uses H1N1 as a Teaching Tool 56956 1Professor Uses H1N1 as a Teaching Tool 56956 2Professor Uses H1N1 as a Teaching Tool 56956 3Muslim Coalition to Host D C Hearing on Health Care Reform 56951 1Muslim Coalition to Host D C Hearing on Health Care Reform 56951 2
... ranged from 1.39 to 1.73, BOSTON, Oct. 26 Shire...al specialty biopharmaceutical company, today,anno...dexamfetamine,dimesylate) effect size. These findi...psychiatrists in Boston. Effect size is a standard...ess of medications evaluated in,different studies ...
...ome are more likely than their unaffected siblings...h obesity, according to pediatric,researchers. The...er risk,of obesity among children and adults with ...,s Hospital of Philadelphia and the,University of ...udy online,today in the Journal of Pediatrics., T...
Other Medicine Technology:Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting 2Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting 3Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting 4Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting 5Obesity-Related Hormone is Higher in Children with Down Syndrome 2
(Date:11/9/2009)...y finds , , MONDAY, Nov. 9 (HealthDay Ne...ial enlargement, which increases the risk of atria...s. , Atrial fibrillation is the most common typ...tbeat). , Researchers analyzed data on 1,212 m...ollowed for 10 years. The study authors concluded ...
(Date:11/9/2009)...rybody,s buzz word today and for Recruiters and St...cruiters and Staffers create their own private net...d close positions. The site also enables individua...ith recruiters. , (PRWEB)...ryone to network more than ever and by the launch ...
(Date:11/9/2009)...od despite similar weight loss , , MONDA...-carbohydrate diet such as the popular Atkins prog...eople lose pounds over the course of a year. ,...lt in long-term improvement in mood, according to ...al Medicine . , People on both diets consumed r...
(Date:11/9/2009)...irstCall/ - Hard To Treat Diseases (HTDS.PK) www.... US$41 billion international healthcare company, i...tner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Lt...ll begin a five-year, $1 billion China initiative ...ase its investment in its China R&D facility, ...
(Date:11/9/2009)...ered in April 2010, Provides First Responders with...bridge, MA (Vocus) November 9, 2009 -- When Stefan...t inspected a suspected mass grave at Dasht-e-Lei...am of experts to help interpret the scene. He knew...t step in securing evidence of a human rights viol...
Breaking Medicine News(10 mins):Health News:Launching StaffingClub.com, a New Online Networking Platform for Recruiting and Staffing Professionals 2Health News:To Feel Better, Low-Fat Diet May Be Best 2Health News:To Feel Better, Low-Fat Diet May Be Best 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4
... & Health Insurance Company (ELH), a subsidiar...IHI ), announced today that it will add vision to ...vision products include a vision insurance plan an...of the most requested employee benefits from a car...
...Relief and Development (LIFE), a U.S.-based charit...ef to the civilian victims of the recent conflict ...ational non-governmental organizations operating i...itarian corridor. , , LIFE has distributed food...
...nsider strategic alternatives , , MADISON, Wis., ... of Avalon Capital Group, announced that on Decemb...ve on the board of TomoTherapy Inc. (Nasdaq: TOM...in TomoTherapy,s stock price since 2007. The compa...
...rom itraconazole, study finds , , MONDAY,...y offer hope for severe asthma patients who also s...ritish study says. , A twice-daily dose of itracon...st one of seven different common fungi in the doub...
...ra, Inc.,(NYSE: HSP ), a global specialty pharma...nounced that Christopher B. Begley, chairman and c...or vice president, Finance, and,chief financial of... in San Francisco. , The presentation is ...
...ence in a high-fat diet can not only lead to overw...o can affect the balance of circadian rhythms eve...y of Jerusalem researchers have shown. , The bio...henomena as hormone imbalance, obesity, psychologi...
Other Medicine News:Health News:Eastern Life & Health Introduces New Vision Product 2Health News:Eastern Life & Health Introduces New Vision Product 3Health News:Avalon Portfolio Nominates Slate of Directors for TomoTherapy Board 2Health News:Avalon Portfolio Nominates Slate of Directors for TomoTherapy Board 3Health News:Another reason to avoid high-fat diet -- it can disrupt our biological clock 2
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...
Medicine Products: